Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8+ T-cell responses
Open Access
- 18 May 2020
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (10), 2143-2157
- https://doi.org/10.1182/bloodadvances.2019001091
Abstract
Patients with chronic lymphocytic leukemia (CLL) are characterized by monoclonal expansion of CD5+CD23+CD27+CD19+κ/λ+ B lymphocytes and are clinically noted to have profound immune suppression. In these patients, it has been recently shown that a subset of B cells possesses regulatory functions and secretes high levels of interleukin 10 (IL-10). Our investigation identified that CLL cells with a CD19+CD24+CD38hi immunophenotype (B regulatory cell [Breg]–like CLL cells) produce high amounts of IL-10 and transforming growth factor β (TGF-β) and are capable of transforming naive T helper cells into CD4+CD25+FoxP3+ T regulatory cells (Tregs) in an IL-10/TGF-β-dependent manner. A strong correlation between the percentage of CD38+ CLL cells and Tregs was observed. CD38hi Tregs comprised more than 50% of Tregs in peripheral blood mononuclear cells (PBMCs) in patients with CLL. Anti-CD38 targeting agents resulted in lethality of both Breg-like CLL and Treg cells via apoptosis. Ex vivo, use of anti-CD38 monoclonal antibody (mAb) therapy was associated with a reduction in IL-10 and CLL patient-derived Tregs, but an increase in interferon-γ and proliferation of cytotoxic CD8+ T cells with an activated phenotype, which showed an improved ability to lyse patient-autologous CLL cells. Finally, effects of anti-CD38 mAb therapy were validated in a CLL–patient-derived xenograft model in vivo, which showed decreased percentage of Bregs, Tregs, and PD1+CD38hiCD8+ T cells, but increased Th17 and CD8+ T cells (vs vehicle). Altogether, our results demonstrate that targeting CD38 in CLL can modulate the tumor microenvironment; skewing T-cell populations from an immunosuppressive to immune-reactive milieu, thus promoting immune reconstitution for enhanced anti-CLL response.This publication has 50 references indexed in Scilit:
- Th17/IL-17A Might Play a Protective Role in Chronic Lymphocytic Leukemia ImmunityPLOS ONE, 2013
- CD19 + CD24 hi CD38 hi B Cells Maintain Regulatory T Cells While Limiting T H 1 and T H 17 DifferentiationScience Translational Medicine, 2013
- T-Regulatory Cells: Key Players in Tumor Immune Escape and AngiogenesisCancer Research, 2012
- REGULATORY T-CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIAMediterranean Journal of Hematology and Infectious Diseases, 2012
- Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemiaBlood, 2011
- CD38 and chronic lymphocytic leukemia: a decade laterBlood, 2011
- The PI3K p110δ Regulates Expression of CD38 on Regulatory T CellsPLOS ONE, 2011
- CD38-mediated Ca2+ Signaling Contributes to Angiotensin II-induced Activation of Hepatic Stellate CellsOnline Journal of Public Health Informatics, 2010
- How Diverse--CD4 Effector T Cells and their FunctionsJournal of Molecular Cell Biology, 2009
- Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drugJCI Insight, 2008